OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
May 03, 2023 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
May 02, 2023 02:00 ET
|
OKYO Pharma LTD
Trial designed with pre-specified primary efficacy endpoints discussed previously with FDAIf successful, this phase 2 trial may serve as one of the two required phase 3 studies necessary to support...
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
April 25, 2023 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
Notice of General Meeting and Publication of Circular
April 05, 2023 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is...
Notice of Intention to Delist From The London Stock Exchange
April 04, 2023 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is...
OKYO Pharma Today Announces Director Acquires Shares
March 30, 2023 02:01 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is...
OKYO Pharma Today Announces Director Acquires Shares
March 29, 2023 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is...
OKYO Pharma Announces PDMR Dealing
March 24, 2023 03:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is...
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
March 16, 2023 03:01 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
March 14, 2023 03:00 ET
|
OKYO Pharma LTD
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER...